J. Kevin Buchi, President and Chief Executive Officer, Awarded the Pennsylvania Bio's Frank Baldino Bioscience CEO of the Year

Malvern, Pennsylvania, UNITED STATES

MALVERN, Pa., March 13, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the Year Award awarded by Pennsylvania Bio, the statewide life sciences industry trade association. Mr. Buchi was honored at PA Bio's Annual Dinner and Awards Celebration and Ceremony on March 12, 2014 in Philadelphia.

The Baldino Award recognizes a CEO who has shown visionary leadership, exceptional achievement and unerring commitment to patients and the industry.

"It is a true honor to be selected for this award. I'm especially humbled given my 20 years history of closely working with Frank," stated Mr. Buchi. "Frank always said that his success was based upon the hard work of the people supporting him. That is certainly true for me. We have assembled a terrific team at TetraLogic and this award reflects their achievements."

About TetraLogic

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic the Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct.  Birinapant, our clinical-stage product candidate, is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.


Contact Data